BRAF and melanoma: Approximately a decade ago, Lheure et al. [12] conducted a retrospective analysis of 70 patients treated with vemurafenib for BRAF-mutant advanced melanoma, finding that five (7.1%) developed SLR, a rate higher than typically expected for melanoma.